MiNK Therapeutics, Inc.

Thank you for standing by. I would like to welcome everyone to the Mink Therapeutics Third Quarter 2024 Financial Results. I would now like to turn the call over to Alexa Buffa from Mink's Corporate Communications. Please go ahead.

Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements including those related to our clinical development, regulatory and commercial plans, time for data releases, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our FDC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, Christine Klaskin, Principal Financial and Accounting Officer, Dr. Nels Redquist, Director of Research, and Dr. Paul Evett, Scientist at Manx. Now, I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter.

Thank you, Alexa. Good morning, and thank you all for joining us today.